Background: Patients undergoing endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms can exhibit variations in sac behavior ranging from complete regression to expansion. We evaluated the impact of sac behavior at 1-year follow-up on late survival.
Since the introduction of endovascular aneurysm repair (EVAR) by Juan Parodi in 1991, 1 EVAR has become the dominant approach to management of abdominal aortic aneurysms (AAAs). [2] [3] [4] Although there is a clear early survival benefit of EVAR, randomized controlled trials and large studies of Medicare beneficiaries show lower late survival in EVAR patients compared with open repair. [5] [6] [7] [8] Late complications from EVAR include a need for reinterventions, conversion to open repair, and rupture. Many of the reinterventions after EVAR are performed for endoleaks. 6 Whereas type I and type III endoleaks are generally considered to be procedural complications that necessitate intervention, type II endoleaks have (e-mail: vp2385@cumc.columbia.edu; virendraipatel23@gmail.com).
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previously been thought to be more benign. Several studies have shown that persistent type II endoleaks independently predict aneurysm sac enlargement, which is often sufficient justification for reintervention. [9] [10] [11] [12] However, not all patients with type II endoleaks develop sac enlargement, and the predictors of sac behavior after EVAR are less well known. In addition, the impact of aneurysm sac behavior on long-term survival after EVAR is unknown. Therefore, we aimed to identify predictors of AAA sac size enlargement or regression and to evaluate the impact of change in sac size on longterm survival after EVAR.
METHODS
The Massachusetts General Hospital Institutional Review Board approved this study and waived informed consent because of the use of deidentified data collected in conjunction with a regional quality improvement initiative.
Population. This is a retrospective cohort study evaluating outcomes of patients undergoing EVAR (2003-2011) using data from the Vascular Study Group of New England (VSGNE) registry. The VSGNE is a regional collaboration developed in 2002 that currently consists of 31 academic and community hospitals throughout six New England states. The registry includes prospectively collected data on commonly performed vascular procedures from each participating institution. Further details on this registry have been published and are available at www.vsgne.org. 13 For this study, patients who underwent EVAR for rupture were excluded. Because the primary objective was to evaluate the relationship between sac behavior at 1-year follow-up and mortality, those patients with no 1-year follow-up imaging data were excluded (n ¼ 635 [26%]). To evaluate sac behavior, maximum anteroposterior aortic diameter at 1-year follow-up, per the VSGNE definition, was compared with preoperative aortic diameter. Sac expansion was defined as an increase of at least 5 mm and sac regression was defined as a decrease of at least 5 mm per Society for Vascular Surgery guidelines.
14 Stable sac size was defined as a change <5 mm in either direction. Of note, imaging modality was not recorded within the Vascular Quality Initiative registry, but at a minimum, all patients had sufficient imaging to determine sac diameter (ie, computed tomography, magnetic resonance imaging, ultrasound, or arteriography) to be eligible for inclusion in this study. Statistical analysis. All ordinal data were presented as absolute number and percentage prevalence in the study population, and all continuous data were presented as median (interquartile range). Univariate analysis comparing sac expansion with stable sac or sac regression was performed using Fisher exact test for discrete variables and the Mann-Whitney U test for non-normally distributed continuous variables. Multivariable logistic regression modeling was used to identify variables associated with sac expansion and sac regression. Actuarial survival was evaluated using Kaplan-Meier life-table analysis, and log-rank testing was used to compare survival of those with sac expansion with survival of those with stable sac or sac regression. Riskadjusted late mortality risk was determined using multivariable Cox proportional hazards modeling. All tests were two sided, and a P value of <.05 was considered significant. Statistical data analysis was performed using Stata version 14.1 software (StataCorp LP, College Station, Tex). Recommendation: Sac expansion after endovascular aneurysm repair warrants close observation and perhaps early intervention.
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RESULTS
Demographics.
Using the VSGNE registry, we identified 2437 patients undergoing EVAR during the study period, of whom 1802 (74%) had 1-year anatomic follow-up data and were included in the primary analysis. Of these, 162 (9%) had sac expansion, 709 (39%) had a stable sac, and 931 (52%) had sac regression. As shown in Table I , patients with sac expansion were older (76 vs 74; P ¼ .03), more frequently had preoperative renal insufficiency (5.0% vs 2.0%; P ¼ .03), and were less likely to smoke (19% vs 30%; P < .01). Those with sac expansion were found to have a trend toward more frequently having had prior aortic surgery (4.3% vs 2.0%; P ¼ .08).
Operative details. There was no difference in preoperative aortic diameter in those with and without sac expansion (56 vs 55 mm; P ¼ .43) or in the presence of concomitant iliac aneurysm (24% vs 22%; P ¼ .62); however, among patients with iliac artery aneurysms, the maximum iliac artery diameter was greater in patients who eventually developed sac expansion (36.5 vs 25 mm; P < .001). Those with sac expansion were more likely to have had an urgent presentation (9.3% vs 4.5%; P ¼ .01). Operative time, blood loss, graft configuration, and graft type were similar between groups (Table II) . There was no difference between those with sac expansion and those without in overall occurrence of concomitant procedures (37% vs 37%; P ¼ 1.0), including graft extension (sac increase, 8.0%; stable or decrease, 9.7%; P ¼ .66), but those with sac expansion were more likely to have undergone hypogastric artery coiling or coverage (25% vs 17%; P ¼ .02) and renal artery angioplasty and stenting (5.3% vs 2.5%; P ¼ .06). Those with sac expansion were less likely to have undergone iliac artery angioplasty (1.3% vs 5.3%; P ¼ .03). There was a trend toward higher rates of any completion endoleak in those who later developed sac expansion (32% vs 26%; P ¼ .08). Whereas more patients who developed sac expansion had completion type I (3.7% vs 1.8%; P ¼ .13) and type II (27% vs 22%; P ¼ .14) endoleaks, these relationships were not statistically significant. Rates of type III endoleak were very low and no different between those with eventual sac expansion and those without (0% vs 0.4%; P ¼ 1.0).
One-year outcomes. At 1-year follow-up, 81% of patients had no endoleak, 1.5% had type I endoleak, and 15% had type II endoleak. Patients with sac expansion were more likely to have endoleaks of each type than those with a stable aneurysm sac, who were more likely to have endoleaks than those with sac regression (expansion, 43%; stable, 26%; regression, 10%; P < .001; Table III) . Of note, 57% of patients with sac expansion had no endoleak, and 26% of patients with type II endoleak had sac regression. By 1 year, 5.6% of patients underwent a secondary intervention, with higher reintervention rates among patients with sac expansion compared with those without (17% vs 4.6%; P < .001).
Predictors of sac behavior. After multivariable adjustment, independent predictors of sac expansion were preoperative renal insufficiency (odds ratio [OR], 3.4; Long-term survival. Long-term survival shown in the Fig was lower (log-rank, P < .001) in patients with sac expansion (98% 1-year and 68% 5-year survival) compared with all others (99% 1-year and 83% 5-year survival). After adjusting for age, sex, comorbidities known to affect survival, history of prior aortic surgery, concomitant procedures, presence of endoleak at 1 year, and reinterventions (Table V) , sac expansion Among patients with 1-year follow-up data, we identified a 15% rate of type II endoleak, which is comparable to the 10% to 20% rates identified in the literature, [24] [25] [26] [27] including a recent meta-analysis of >20,000 patients with a 10.2% rate of type II endoleak. 28 However, of the 1515 patients with type II endoleak, only 1% eventually experienced aneurysm rupture, 28 which again suggests that type II endoleak may be ominous only in certain clinical scenarios. In this cohort, we not surprisingly found that reintervention rate was significantly higher in patients with sac expansion compared with those without sac expansion. Although sac expansion is often attributed to endoleak, not all patients with endoleak develop sac expansion, and not all patients with sac expansion have identifiable endoleak. 23, 29 We also demonstrated this, as more than half of patients with sac expansion had no identifiable endoleak, and roughly one-quarter of patients with type II endoleak still had sac regression. Whereas our rate of no identifiable endoleak among patients with sac expansion was high at 57%, other centers have also shown high rates ranging from 22% to 43%. [30] [31] [32] The reason for the discrepancy in our rate and the rate of others is perhaps because sac expansion in our cohort could have been defined on the basis of ultrasound alone, and it is unclear whether these patients underwent imaging that could have identified an endoleak, whereas in other studies, all patients underwent computed tomography imaging. Other potential explanations include the possibility of a methodologic error inherent in the VSGNE data set in which endoleaks are self-reported by participating centers without any core imaging laboratory adjudication. Finally, detection of an endoleak is not always obvious and can depend on the timing of intravenous administration of the contrast agent or the technologist's experience if duplex ultrasound is used, or it may require multiple modalities for diagnosis. The EVAR 1 trial identified sac expansion as an independent predictor of late rupture, 19 and other series have also suggested that when type II endoleak is associated with sac expansion, reintervention to prevent late rupture and other adverse outcomes may be warranted. 12, 33 Candell et al 17 reported on a large, multicenter U.S. series with 10 years of follow-up. Of 15 patients with late rupture, 10 were known to have sac expansion preceding rupture. Conversely, sac regression is associated with treatment success. Houbballah et al 34 showed that significant sac regression >75% was associated with significantly lower rates of endoleak and reintervention, and no patients with significant sac regression experienced late aneurysm rupture. We observed that the 5-year survival rate is markedly lower among patients with sac expansion (68% vs 83%). Notably, all patients who died within the first postoperative year (6.4% of the cohort) were excluded from this analysis, which compared patients on the basis of 1-year follow-up data. Sensitivity analyses by including these patients with the stable sac or sac regression cohorts showed similar results, leading to the same conclusions as presented. After adjusting for age, patient sex, comorbidities including renal insufficiency, history of prior aortic surgery, operative differences including urgency of repair, persistent endoleak, and reinterventions, sac expansion was associated with increased mortality, and sac regression was associated with lower mortality. The simultaneous observation of risk-adjusted lower survival in patients with sac expansion and higher survival associated with sac regression suggests that sac behavior is likely a surrogate for aneurysm-related mortality.
Notably, sac behavior was more predictive of mortality than presence of any type of endoleak or the need for reintervention. Many prior studies have suggested that the increased late mortality after EVAR compared with open repair in some patients is partly explained by graft complications, endoleak, late conversion to open, and late rupture [5] [6] [7] 17 ; however, no study to our knowledge has specifically associated sac behavior with late mortality. It appears that sac expansion, even in the absence of identifiable endoleak, is more strongly associated with late mortality than endoleak alone. This is further corroborated by the recent 15-year follow-up data from the EVAR 1 trial that showed higher rates of late aneurysmrelated mortality attributable to late aneurysm rupture in EVAR patients, although that study did not directly report on sac expansion as a precursor to rupture. 35 Given the impact of sac behavior on survival, we additionally sought to identify clinical and operative predictors of aneurysm sac enlargement and regression 1 year after EVAR. Although endoleak and sac expansion were not perfectly linked, we still demonstrated a correlation on univariate analysis (P < .001), and both type I/III and type II endoleaks were significant positive predictors of sac expansion and negative predictors of sac regression. Several studies have reported a positive correlation between type II endoleak and sac enlargement. 9, 10, 12 The management of sac expansion in the absence of endoleak merits further investigation, although it is clear this is not a benign process. Even when controlling for patients who underwent reinterventions and for patients with expansion without endoleak, sac expansion is associated with lower survival. It is not clear what is contributing to the worse survival, even among patients without identifiable endoleak. One possible explanation is that these patients have increased graft porosity with endotension. We are unable to account for this in this analysis, but notably, adjusting for graft type did not mitigate this disparity. There also may be patients with endoleaks not captured on follow-up imaging. We anticipate that the number of these patients is small, as most vascular surgeons who identify sac expansion would likely pursue additional imaging. If endoleak was not identified even on computed tomography scan, those patients with sac expansion may then benefit from aortic angiography to identify endoleaks not found on routine imaging and intervention as necessary in appropriate-risk patients.
There are several limitations to this study, including those inherent to the clinical registry used for data collection, such as misclassification and missing data. As our primary objective was to evaluate the association between sac behavior 1 year postoperatively and longterm outcomes, all patients with missing 1-year followup data, including all those who died in the first year, were excluded. Whereas this leads to a clear selection bias, the nature of our study question necessitates exclusion of these patients, and sensitivity analysis showed no changes in conclusion. We are unable in this analysis to account for management of the inferior mesenteric artery, use of instructions for use, 11 or use of preoperative 
CONCLUSIONS
This study demonstrated that AAA sac expansion >5 mm at 1 year, although infrequent, is an independent predictor of late mortality, even after adjusting for presence of endoleak and occurrence of secondary intervention. Even in the absence of identifiable endoleak, sac expansion is not a benign process, and it warrants close observation, potentially additional imaging, and intervention in good-risk patients to influence sac regression, which has survival benefit. The authors have demonstrated an association of aneurysm sac expansion with late mortality in patients treated with endovascular aneurysm repair. However, there are several important limitations of this large cohort study that bear noting.
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The cause of death was unknown, and therefore a causal relationship between aneurysm sac expansion and late mortality can only be inferred. The authors have noted that sac expansion was more predictive of mortality than the presence of any type of endoleak or the need for reintervention. However, sac expansion could not be shown to be a precursor of rupture in this study.
In addition, the imaging modality used in the follow-up of patients in this study was unknown, so it is possible that endoleaks could have been underestimated. For example, if duplex ultrasound scanning was used instead of computed tomography or conventional angiography, an endoleak could have been missed. The authors noted that they anticipated the number of such patients would be small because most vascular surgeons would likely pursue additional imaging if sac expansion without endoleak was identified on duplex ultrasound alone.
Patients with sac expansion were still noted to have lower survival after adjusting for differences in age, patient sex, operative differences, comorbidities,
